Blood biochemical landscape and new insights into clinical decision-making for polycystic ovary syndrome in Chinese women: a prospective cohort study

IntroductionThe Polycystic ovary syndrome (PCOS), a prevalent endocrine disorder affecting women’s reproductive and metabolic health, faces diagnostic challenges due to heterogeneous clinical presentations and the absence of reliable biomarkers. This study investigates the role of Glucosaminyl (N-ac...

Full description

Saved in:
Bibliographic Details
Main Authors: Yutong Li, Xiufeng Lin, Ke Zou, Jing Du, Qingni Li, Linkun Zhong, Shan Jiang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Endocrinology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2025.1534733/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850260179841449984
author Yutong Li
Yutong Li
Xiufeng Lin
Ke Zou
Jing Du
Qingni Li
Linkun Zhong
Shan Jiang
author_facet Yutong Li
Yutong Li
Xiufeng Lin
Ke Zou
Jing Du
Qingni Li
Linkun Zhong
Shan Jiang
author_sort Yutong Li
collection DOAJ
description IntroductionThe Polycystic ovary syndrome (PCOS), a prevalent endocrine disorder affecting women’s reproductive and metabolic health, faces diagnostic challenges due to heterogeneous clinical presentations and the absence of reliable biomarkers. This study investigates the role of Glucosaminyl (N-acetyl) transferase 2 (GCNT2) in modulating sex hormone-binding globulin (SHBG) and its potential as a therapeutic target in PCOS pathophysiology.MethodsA prospective cohort of 103 PCOS patients treated with oral contraceptives (2021–2024) was established. Bidirectional Mendelian randomization (MR) was employed to assess genetic associations and causal relationships between PCOS and SHBG. Molecular docking studies evaluated cryptotanshinone’s binding affinity to key proteins (COL1A1, COL4A2, COL6A2) in the PI3K/Akt pathway. GCNT2’s regulatory effects on collagen synthesis and extracellular matrix pathways. Pharmacokinetic profiling validated therapeutic viability.ResultsBidirectional MR revealed significant genetic associations (P < 0.001) and causal links between PCOS and SHBG, implicating GCNT2 as a key modulator. Cryptotanshinone exhibited strong binding affinity to PI3K/Akt signaling pathway proteins and favorable pharmacokinetic properties. Enrichment analyses highlighted GCNT2’s role in collagen biosynthesis (FDR < 0.05) and extracellular matrix regulation.DiscussionThis study identifies GCNT2 as a critical mediator of PCOS pathophysiology through SHBG modulation and collagen remodeling. Cryptotanshinone emerges as a promising therapeutic candidate, targeting PI3K/Akt signaling pathway with high specificity. These findings advance the understanding of PCOS mechanisms and provide a foundation for biomarker-driven diagnostics and precision therapeutics. Further validation in clinical trials is warranted to translate these insights into practice.
format Article
id doaj-art-91f2d71f850848ecb1d7404bf35a3298
institution OA Journals
issn 1664-2392
language English
publishDate 2025-05-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Endocrinology
spelling doaj-art-91f2d71f850848ecb1d7404bf35a32982025-08-20T01:55:41ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922025-05-011610.3389/fendo.2025.15347331534733Blood biochemical landscape and new insights into clinical decision-making for polycystic ovary syndrome in Chinese women: a prospective cohort studyYutong Li0Yutong Li1Xiufeng Lin2Ke Zou3Jing Du4Qingni Li5Linkun Zhong6Shan Jiang7The First Clinical College, Guangdong Medical University, Zhanjiang, Guangdong, ChinaDepartment of General Surgery, Zhongshan City People’s Hospital, Zhongshan, Guangdong, ChinaReproductive Center, Boai Hospital of Zhongshan, Zhongshan, Guangdong, ChinaThe First Clinical College, Guangdong Medical University, Zhanjiang, Guangdong, ChinaReproductive Center, Boai Hospital of Zhongshan, Zhongshan, Guangdong, ChinaReproductive Center, Boai Hospital of Zhongshan, Zhongshan, Guangdong, ChinaDepartment of General Surgery, Zhongshan City People’s Hospital, Zhongshan, Guangdong, ChinaReproductive Center, Boai Hospital of Zhongshan, Zhongshan, Guangdong, ChinaIntroductionThe Polycystic ovary syndrome (PCOS), a prevalent endocrine disorder affecting women’s reproductive and metabolic health, faces diagnostic challenges due to heterogeneous clinical presentations and the absence of reliable biomarkers. This study investigates the role of Glucosaminyl (N-acetyl) transferase 2 (GCNT2) in modulating sex hormone-binding globulin (SHBG) and its potential as a therapeutic target in PCOS pathophysiology.MethodsA prospective cohort of 103 PCOS patients treated with oral contraceptives (2021–2024) was established. Bidirectional Mendelian randomization (MR) was employed to assess genetic associations and causal relationships between PCOS and SHBG. Molecular docking studies evaluated cryptotanshinone’s binding affinity to key proteins (COL1A1, COL4A2, COL6A2) in the PI3K/Akt pathway. GCNT2’s regulatory effects on collagen synthesis and extracellular matrix pathways. Pharmacokinetic profiling validated therapeutic viability.ResultsBidirectional MR revealed significant genetic associations (P < 0.001) and causal links between PCOS and SHBG, implicating GCNT2 as a key modulator. Cryptotanshinone exhibited strong binding affinity to PI3K/Akt signaling pathway proteins and favorable pharmacokinetic properties. Enrichment analyses highlighted GCNT2’s role in collagen biosynthesis (FDR < 0.05) and extracellular matrix regulation.DiscussionThis study identifies GCNT2 as a critical mediator of PCOS pathophysiology through SHBG modulation and collagen remodeling. Cryptotanshinone emerges as a promising therapeutic candidate, targeting PI3K/Akt signaling pathway with high specificity. These findings advance the understanding of PCOS mechanisms and provide a foundation for biomarker-driven diagnostics and precision therapeutics. Further validation in clinical trials is warranted to translate these insights into practice.https://www.frontiersin.org/articles/10.3389/fendo.2025.1534733/fullcryptotanshinoneglucosaminyl (N-acetyl) transferase 2SHBGpolycystic ovary syndromeMendelian randomization (MR)
spellingShingle Yutong Li
Yutong Li
Xiufeng Lin
Ke Zou
Jing Du
Qingni Li
Linkun Zhong
Shan Jiang
Blood biochemical landscape and new insights into clinical decision-making for polycystic ovary syndrome in Chinese women: a prospective cohort study
Frontiers in Endocrinology
cryptotanshinone
glucosaminyl (N-acetyl) transferase 2
SHBG
polycystic ovary syndrome
Mendelian randomization (MR)
title Blood biochemical landscape and new insights into clinical decision-making for polycystic ovary syndrome in Chinese women: a prospective cohort study
title_full Blood biochemical landscape and new insights into clinical decision-making for polycystic ovary syndrome in Chinese women: a prospective cohort study
title_fullStr Blood biochemical landscape and new insights into clinical decision-making for polycystic ovary syndrome in Chinese women: a prospective cohort study
title_full_unstemmed Blood biochemical landscape and new insights into clinical decision-making for polycystic ovary syndrome in Chinese women: a prospective cohort study
title_short Blood biochemical landscape and new insights into clinical decision-making for polycystic ovary syndrome in Chinese women: a prospective cohort study
title_sort blood biochemical landscape and new insights into clinical decision making for polycystic ovary syndrome in chinese women a prospective cohort study
topic cryptotanshinone
glucosaminyl (N-acetyl) transferase 2
SHBG
polycystic ovary syndrome
Mendelian randomization (MR)
url https://www.frontiersin.org/articles/10.3389/fendo.2025.1534733/full
work_keys_str_mv AT yutongli bloodbiochemicallandscapeandnewinsightsintoclinicaldecisionmakingforpolycysticovarysyndromeinchinesewomenaprospectivecohortstudy
AT yutongli bloodbiochemicallandscapeandnewinsightsintoclinicaldecisionmakingforpolycysticovarysyndromeinchinesewomenaprospectivecohortstudy
AT xiufenglin bloodbiochemicallandscapeandnewinsightsintoclinicaldecisionmakingforpolycysticovarysyndromeinchinesewomenaprospectivecohortstudy
AT kezou bloodbiochemicallandscapeandnewinsightsintoclinicaldecisionmakingforpolycysticovarysyndromeinchinesewomenaprospectivecohortstudy
AT jingdu bloodbiochemicallandscapeandnewinsightsintoclinicaldecisionmakingforpolycysticovarysyndromeinchinesewomenaprospectivecohortstudy
AT qingnili bloodbiochemicallandscapeandnewinsightsintoclinicaldecisionmakingforpolycysticovarysyndromeinchinesewomenaprospectivecohortstudy
AT linkunzhong bloodbiochemicallandscapeandnewinsightsintoclinicaldecisionmakingforpolycysticovarysyndromeinchinesewomenaprospectivecohortstudy
AT shanjiang bloodbiochemicallandscapeandnewinsightsintoclinicaldecisionmakingforpolycysticovarysyndromeinchinesewomenaprospectivecohortstudy